Pathos AI Signs Strategic Agreements with AstraZeneca and Tempus for Oncology Foundation Model
Pathos AI has announced strategic partnerships with pharmaceutical giant AstraZeneca and healthcare technology company Tempus to develop what will be the largest multimodal foundation model in oncology.
Partnership Overview:
The agreements bring together three key players in healthcare AI:
Pathos AI: Contributing its expertise in AI model development and biomedical research
AstraZeneca: Providing pharmaceutical industry knowledge, drug development expertise, and access to clinical data
Tempus: Contributing its large-scale clinical data platform and genomic sequencing capabilities
Foundation Model for Oncology:
The planned multimodal foundation model will integrate genomic data from tumor sequencing, clinical notes and pathology reports, medical imaging, treatment outcomes, and scientific literature. This comprehensive approach aims to accelerate drug discovery, improve patient stratification for clinical trials, and develop more personalized treatment recommendations.
Details
- City
- Cambridge
- Organization
- AstraZeneca
- Continent
- Europe
- Country
- United Kingdom
- Category
- Pharmaceuticals
- Type
- Deployment
- Id
- eff45a2b-7b6a-43ec-a05e-34a5f7be3144
- Created At